Uncategorized

$SGLB Featured in Discussion of Full Promise of 3D-Printing Technology

NEW YORK, Dec. 05, 2019 — via NetworkNewsAudio –  Sigma Labs Inc. (NASDAQ: SGLB) announces the availability of a broadcast titled, “Unleashing the Disruptive Forces of 3D Printing.”

To hear the NetworkNewsWire Audio version, visit:  http://nnw.fm/1T7jm

To read the full editorial, visit: http://nnw.fm/g3zSt

PrintRite3D 5.1 uniquely leverages thermal signatures to monitor the quality of each product part in the production process, layer by layer and in real time. This allows operators to correct or stop production of a defective part, resulting in reduced error rates and higher yields. This incredibly sophisticated and powerful technology may hold enormous potential value.

To date, Sigma Labs Inc. (NASDAQ: SGLB) has engaged 19 beta customers, including many of the biggest names in the industry, with more evaluation programs likely to follow. Two of these programs have already awarded Sigma Labs Phase 2 contracts for its rapid test and evaluation program, the last step before full commercial orders. The first Phase 2 contract, revealed on the Q3 earnings call, was awarded by Baker Hughes; the second contract was recently awarded by IAPT.

About Sigma Labs

Sigma Labs Inc. (NASDAQ: SGLB) is an emerging provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D for 3D advanced-manufacturing technologies. Sigma Labs’ advanced, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time. For more information, please visit www.SigmaLabsInc.com.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Thursday, December 5th, 2019 Uncategorized Comments Off

$CNPOF $RIV.V UCSD Researchers Study Possible Benefits and Risks of Cannabidiol

December 5, 2019

Cannabidiol (CBD) has achieved what very few products have. From being barely known, CBD has grown so quickly that it is estimated the cannabidiol market will be worth at least $20 billion in sales by 2026. However, there’s a good reason why most new products have to go through a lengthy approval period before hitting the shelves. Especially products that claim to cure a variety of diseases.

Given the sheer amount of CBD products on the market right now, estimated to be in the thousands, one would think that regulatory authorities have properly vetted and approved them. The truth is, the U.S. Food and Drug Administration (FDA) has been playing catch up, trying to keep up with a runaway industry that has been referred to as the Wild West.

Looking to form a more coherent picture of cannabidiol, The Center for Medical Cannabis Research (CMBR) at UC San Diego (UCSD) has been doing extensive research on the risks and especially the benefits that a lot of the CBD products on the market claim. The CMBR has awarded five teams grants to research the different uses of CBD including alleviating the symptoms of arthritis, alcohol dependence, and other forms of drug dependence.

Igor Grant, CMBR Director, is pushing for even more research on cannabidiol’s efficacy.

One important fact gleaned from the research was that despite the lack of third party testing and regulation around CBD products, there is significant interest in cannabidiol products, especially online. “Within the medical community, there is a lot of interest in the role of medical cannabis and CBD. There is hope that it could be yet another useful agent in some of these conditions, which are disabling or difficult to treat.”

CBD has indeed grown popular. In fact, CBD gummies were the third most searched for food in America in 2018 and each of these searches was done by someone looking to benefit from cannabidiol. The hemp extract is a potent and versatile natural medicine, said to be effective against an almost never-ending list of medical conditions.

While there’s little research to prove whether or not this is true, anecdotal evidence says the compound works against conditions ranging from anxiety, high blood pressure, and chronic pain. Another UCSD study found that CBD oil is being used by consumers to treat alcohol dependence and physical pain brought about by conditions like arthritis.

John W. Ayers, Vice Chief of Innovation in the Division of Infectious Disease and Global Public Health at UCSD, concurs with the study’s findings. “CBD has become insanely popular. Three years ago there was essentially no one searching for CBD online, but now there are an estimated 6.4 million unique searches each month.”

The UCSD cautions consumers against using CBD as an alternative to pharmaceuticals in cases that haven’t been tested in a clinical trial.

It remains to be seen whether this research brings up anything that would surprise CBD companies like Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) and ChineseInvestors.com Inc. (OTCQB: CIIX).

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Thursday, December 5th, 2019 Uncategorized Comments Off

$OGI US FDA Breakthrough Therapy Designation for Mushrooms Creating Big Opportunity

Palm Beach, FL – December 5, 2019 — For the second year, the U.S. FDA designated psilocybin, a compound found in hallucinogenic mushrooms, as a “breakthrough therapy” for the treatment of major depressive disorder (MDD). “This designation, which is designed to expedite the development and review of drugs—given out only for therapies that have shown strong preliminary evidence in treating serious medical conditions—puts new pharmaceuticals on a fast track for approval and offers “intensive guidance” from the FDA,” reports Popular Science.  Even Researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.  That’s all opening a range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), HEXO Corporation (NYSE:HEXO) (TSX:HEXO), Trulieve Cannabis Corp. (CSE:TRUL)(OTCQX:TCNNF), The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF), and OrganiGram Holdings Inc. (NASDAQ:OGI)(TSX-V:OGI).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWSThe Yield Growth Corp. just announced that its subsidiary Flourish Mushroom Labs Inc. has started initial consumer tasting trials for four organic mushroom coffees using a unique blend of freshly ground coffee beans and various mushroom formulations. “Great emphasis has been given to selecting quality ingredients including mushrooms that exhibit the highest  level of active components, which are assayed in the laboratory to assure efficacy and safety,” says Vivek Taneja, Flourish Mushroom Labs’ VP, Operations. “The consumer tasting trials will involve 100 participants and will take one month to complete and compile results. If results are satisfactory then the next stage of development will commence.”  The newly developed line of coffees contain the mushroom varieties Lion’s Mane, Reishi , Turkey Tale, Cordyceps and Chaga. Lion’s Mane is known to be a powerful brain food that Healthline.com suggests supports memory, focus and cerebral function.  Healthline.com also states that Reishi mushrooms may help boost the immune system, reduce stress, while Turkey Tail is shown to be a powerful antioxidant that improves gut bacteria balance. Cordyceps, according to an article from the US National Library of Medicine, have shown to enhance athletic performance and support longevity. Chaga extracts, according to www.healthline.com, have been used in Russia and Northern European countries mainly to boost immunity and overall health.  These extracts have been used to treat certain cancers, diabetes and heart disease and to lower blood sugar and cholesterol.

“Our research team has collected scientific information, including biological and pharmacological studies related to the chemical constituents and curative effects of medicinal mushrooms from various journals in developing our mushroom formulas These herbs have been used in traditional Chinese and Ayurvedic medicine for thousands of years as food for optimum health,” says Bhavna Solecki, VP, Research and Development at Flourish Mushroom Labs.

Other related developments from around the markets include:

 

HEXO Corporation (NYSE:HEXO) (TSX:HEXO) just launched Original Stash, its new value brand, in Ontario on Black Friday.  Adult-use consumers in Ontario will be able to purchase 28 grams (1 oz) of quality dried cannabis flower at black market prices, retailing at $140 ($5 per gram), including taxes. “HEXO is disrupting the black market this Black Friday,” said Sebastien St-Louis, CEO and co-founder of HEXO. “We are committed to playing a valuable role in eliminating the illicit market and in protecting public health and safety. That’s why we are pleased to continue rolling out Original Stash across Canada, providing consumers with a quality product at a low price. Our experience with the launch of Original Stash in October demonstrates that there is a strong demand for this type of product.” HEXO is launching OS.220, the second dried flower product to roll out from the Original Stash brand, in Ontario. OS.220 is a mid-THC Indica flower blend of two strains, available in a 28 g (1 oz) format. The Ontario Cannabis Store is poised to make Original Stash available on its webstore and to all licensed retailers in the province, who can in turn choose to carry the brand. HEXO’s Original Stash will be the first brand to be featured as part of the Ontario Cannabis Store’s inaugural homepage holiday campaign, in conjunction with Black Friday. “Original Stash is providing consumers with ‘quality weed at legit prices’,” added St-Louis. “Consistent, reliable and controlled products like this can play a major role in achieving the goals we set out nationally by legalizing cannabis just over a year ago: eliminating the illicit market and protecting public health and safety. We look forward to continuing to work with our regulators and partners to deliver on those objectives.”

Trulieve Cannabis Corp. (CSE:TRUL)(OTCQX:TCNNF) announced that CEO Kim Rivers will be featured on a presenting panel Multi-State Operators take on Medicinal Cannabis speaking with other leading cannabis executives in the healthcare sector at Piper Jaffray’s 31st Annual Healthcare Conference  at 4:00 p.m. EST on Tuesday, December 3rd, 2019. This two-day event is being held in New York City, and will bring together institutional investors and nearly 300 leading public and private companies in various health care services sectors such as biotechnology and specialty pharmaceuticals.  In addition, Ms. Rivers is scheduled to speak on the Licensing: Ins and Outs – Ensuring Continued Compliance in a Changing Regulatory Landscape panel at the MJ Biz Conference at 10:30 a.m. PST on Thursday, December 12th, 2019 in Las Vegas.

The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF) just announced that it has entered into an amending agreement with Canaccord Genuity Corp. to increase the size of its previously announced bought deal financing. Pursuant to the revised terms of the offering, the Underwriter has agreed to purchase, on a bought deal basis, an aggregate of 32,000,000 units (the “Units”) at a price of C$0.75 per Unit for aggregate gross proceeds to TGOD of $24,000,000.  Each Unit will consist of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing of the Offering at an exercise price of C$1.00 per Warrant Share. The Company has granted the Underwriter an option to purchase up to an additional 4,800,000 Units at a price of C$0.75 per Unit, exercisable at any time, for a period of 30 days after and including the Closing Date, which, if exercised, would result in additional gross proceeds of $3,600,000. The Over-Allotment Option is exercisable to acquire Units and/or Warrants at the discretion of the Underwriter.

OrganiGram Holdings Inc. (NASDAQ:OGI)(TSX-V:OGI) announced its results for the fourth quarter and fiscal year ended August 31, 2019. “Our 2019 results reflected a successful year for Organigram. Not only did we report strong top-line growth and establish an enviable national market share position in Canada, we generated positive adjusted EBITDA – one of the key measures we use to evaluate our performance,” said Greg Engel, Chief Executive Officer. “In 2019, we increased staffing and capacity to meet forecasted demand and maintain inventory in the market. Industry structural issues have challenged supply and demand dynamics in the short-term but we believe the growth opportunity in the Canadian cannabis market remains intact. “As we were one of the first success stories to supply the market in the early days of legalization, we have had visibility for some time now on ultimate sell through to consumers and have adapted our production mix and product strategy to align with our understanding of emerging consumer preferences. We have great conviction in our strategy and ability to onboard the new retail store openings and to launch a portfolio of edible and derivative products appealing to adult consumers. With our state-of-the-art indoor facility and leading cultivation practices, strong brand equity, in-house expertise and strategic partnerships and a focus on cost management, we are well-positioned for the long term.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated thirty five hundred dollars for news coverage of current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

Thursday, December 5th, 2019 Uncategorized Comments Off

$TGODF US FDA Breakthrough Therapy Designation for Mushrooms Creating Big Opportunity

Palm Beach, FL – December 5, 2019 — For the second year, the U.S. FDA designated psilocybin, a compound found in hallucinogenic mushrooms, as a “breakthrough therapy” for the treatment of major depressive disorder (MDD). “This designation, which is designed to expedite the development and review of drugs—given out only for therapies that have shown strong preliminary evidence in treating serious medical conditions—puts new pharmaceuticals on a fast track for approval and offers “intensive guidance” from the FDA,” reports Popular Science.  Even Researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.  That’s all opening a range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), HEXO Corporation (NYSE:HEXO) (TSX:HEXO), Trulieve Cannabis Corp. (CSE:TRUL)(OTCQX:TCNNF), The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF), and OrganiGram Holdings Inc. (NASDAQ:OGI)(TSX-V:OGI).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWSThe Yield Growth Corp. just announced that its subsidiary Flourish Mushroom Labs Inc. has started initial consumer tasting trials for four organic mushroom coffees using a unique blend of freshly ground coffee beans and various mushroom formulations. “Great emphasis has been given to selecting quality ingredients including mushrooms that exhibit the highest  level of active components, which are assayed in the laboratory to assure efficacy and safety,” says Vivek Taneja, Flourish Mushroom Labs’ VP, Operations. “The consumer tasting trials will involve 100 participants and will take one month to complete and compile results. If results are satisfactory then the next stage of development will commence.”  The newly developed line of coffees contain the mushroom varieties Lion’s Mane, Reishi , Turkey Tale, Cordyceps and Chaga. Lion’s Mane is known to be a powerful brain food that Healthline.com suggests supports memory, focus and cerebral function.  Healthline.com also states that Reishi mushrooms may help boost the immune system, reduce stress, while Turkey Tail is shown to be a powerful antioxidant that improves gut bacteria balance. Cordyceps, according to an article from the US National Library of Medicine, have shown to enhance athletic performance and support longevity. Chaga extracts, according to www.healthline.com, have been used in Russia and Northern European countries mainly to boost immunity and overall health.  These extracts have been used to treat certain cancers, diabetes and heart disease and to lower blood sugar and cholesterol.

“Our research team has collected scientific information, including biological and pharmacological studies related to the chemical constituents and curative effects of medicinal mushrooms from various journals in developing our mushroom formulas These herbs have been used in traditional Chinese and Ayurvedic medicine for thousands of years as food for optimum health,” says Bhavna Solecki, VP, Research and Development at Flourish Mushroom Labs.

Other related developments from around the markets include:

 

HEXO Corporation (NYSE:HEXO) (TSX:HEXO) just launched Original Stash, its new value brand, in Ontario on Black Friday.  Adult-use consumers in Ontario will be able to purchase 28 grams (1 oz) of quality dried cannabis flower at black market prices, retailing at $140 ($5 per gram), including taxes. “HEXO is disrupting the black market this Black Friday,” said Sebastien St-Louis, CEO and co-founder of HEXO. “We are committed to playing a valuable role in eliminating the illicit market and in protecting public health and safety. That’s why we are pleased to continue rolling out Original Stash across Canada, providing consumers with a quality product at a low price. Our experience with the launch of Original Stash in October demonstrates that there is a strong demand for this type of product.” HEXO is launching OS.220, the second dried flower product to roll out from the Original Stash brand, in Ontario. OS.220 is a mid-THC Indica flower blend of two strains, available in a 28 g (1 oz) format. The Ontario Cannabis Store is poised to make Original Stash available on its webstore and to all licensed retailers in the province, who can in turn choose to carry the brand. HEXO’s Original Stash will be the first brand to be featured as part of the Ontario Cannabis Store’s inaugural homepage holiday campaign, in conjunction with Black Friday. “Original Stash is providing consumers with ‘quality weed at legit prices’,” added St-Louis. “Consistent, reliable and controlled products like this can play a major role in achieving the goals we set out nationally by legalizing cannabis just over a year ago: eliminating the illicit market and protecting public health and safety. We look forward to continuing to work with our regulators and partners to deliver on those objectives.”

Trulieve Cannabis Corp. (CSE:TRUL)(OTCQX:TCNNF) announced that CEO Kim Rivers will be featured on a presenting panel Multi-State Operators take on Medicinal Cannabis speaking with other leading cannabis executives in the healthcare sector at Piper Jaffray’s 31st Annual Healthcare Conference  at 4:00 p.m. EST on Tuesday, December 3rd, 2019. This two-day event is being held in New York City, and will bring together institutional investors and nearly 300 leading public and private companies in various health care services sectors such as biotechnology and specialty pharmaceuticals.  In addition, Ms. Rivers is scheduled to speak on the Licensing: Ins and Outs – Ensuring Continued Compliance in a Changing Regulatory Landscape panel at the MJ Biz Conference at 10:30 a.m. PST on Thursday, December 12th, 2019 in Las Vegas.

The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF) just announced that it has entered into an amending agreement with Canaccord Genuity Corp. to increase the size of its previously announced bought deal financing. Pursuant to the revised terms of the offering, the Underwriter has agreed to purchase, on a bought deal basis, an aggregate of 32,000,000 units (the “Units”) at a price of C$0.75 per Unit for aggregate gross proceeds to TGOD of $24,000,000.  Each Unit will consist of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing of the Offering at an exercise price of C$1.00 per Warrant Share. The Company has granted the Underwriter an option to purchase up to an additional 4,800,000 Units at a price of C$0.75 per Unit, exercisable at any time, for a period of 30 days after and including the Closing Date, which, if exercised, would result in additional gross proceeds of $3,600,000. The Over-Allotment Option is exercisable to acquire Units and/or Warrants at the discretion of the Underwriter.

OrganiGram Holdings Inc. (NASDAQ:OGI)(TSX-V:OGI) announced its results for the fourth quarter and fiscal year ended August 31, 2019. “Our 2019 results reflected a successful year for Organigram. Not only did we report strong top-line growth and establish an enviable national market share position in Canada, we generated positive adjusted EBITDA – one of the key measures we use to evaluate our performance,” said Greg Engel, Chief Executive Officer. “In 2019, we increased staffing and capacity to meet forecasted demand and maintain inventory in the market. Industry structural issues have challenged supply and demand dynamics in the short-term but we believe the growth opportunity in the Canadian cannabis market remains intact. “As we were one of the first success stories to supply the market in the early days of legalization, we have had visibility for some time now on ultimate sell through to consumers and have adapted our production mix and product strategy to align with our understanding of emerging consumer preferences. We have great conviction in our strategy and ability to onboard the new retail store openings and to launch a portfolio of edible and derivative products appealing to adult consumers. With our state-of-the-art indoor facility and leading cultivation practices, strong brand equity, in-house expertise and strategic partnerships and a focus on cost management, we are well-positioned for the long term.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated thirty five hundred dollars for news coverage of current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

Thursday, December 5th, 2019 Uncategorized Comments Off

$POAI Announces Multiple Indications of Interest for Skyline Medical Division

Predictive Oncology Confirms Indications of Interest for Skyline Medical Business

MINNEAPOLIS, Dec. 05, 2019 — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has received indications of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY System for disposal of fluids in medical applications. As previously announced, Predictive Oncology has determined that it will focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery.

Skyline Medical’s patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications. The division has expanded sales globally and made significant inroads in U.S. markets.

Dr. Carl Schwartz, Predictive Oncology’s Chief Executive Officer commented, “I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division. If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine”.

The Company believes it will have updates on the future of its Skyline Medical business by early in 2020. The Company will evaluate its alternatives for the Skyline Medical business in order to maximize value for its stockholders. There is no assurance that the Company will ultimately receive offers for the division that it deems acceptable. Further, there is no assurance that the Company will enter into a definitive agreement or ultimately complete a sale of the division.

About Predictive Oncology Inc.

Predictive Oncology (Nasdaq: POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.predictive-oncology.com.

Forward-looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses, distraction of management and diversion of resources; and the market price of the Company’s common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictive’s ability to implement its long range business plan for various applications of its technology; Predictive’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictive’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictive’s financial position. See Predictive’s most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.

Contact:
Charles Moskowitz
info@MoneyInfo-LLC.com
339-201-7457

Source: GlobeNewswire (December 5, 2019 – 8:30 AM EST)

Thursday, December 5th, 2019 Uncategorized Comments Off

$LXRP DehydraTECH™ Drug Delivery Platform Proven to Enhance Absorption of Bioactive Compounds

December 4, 2019

  • DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins
  • Lexaria has 16 patents granted and over 60 patent applications pending worldwide
  • DehydraTECH™ shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is accelerating its patented DehydraTECH based drug delivery technology and formulation development. Funding received from the first tranche of Lexaria’s previously announced private placement of units, issued at a price of $0.45 per unit, realized gross proceeds of $699,410, which will be used to advance several company-wide goals (http://cnw.fm/vJ8up).

Earlier this year, Lexaria moved into its new head office that includes a Health Canada licensed research and development laboratory that is being used to conduct world-leading research into drug delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://cnw.fm/VV6qg).

Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.

Cannabidiol is emerging as a promising compound to treat or prevent movement disorders, such as those seen in Parkinson’s disease patients, according to an article published by the National Institutes of Health (http://cnw.fm/uI7lD). Extending the range of drugs available for therapeutic use to treat neurological conditions such as Alzheimer’s and Parkinson’s disease is a critical area of study since there currently is no effective treatment for these diseases, according to an article in Physics World (http://cnw.fm/2IlQ6).

Lexaria’s dedication to research and development can be seen in its strong and growing intellectual property portfolio. As of August 2019, the company’s patent portfolio includes approximately 60 patent applications filed and pending in more than 40 countries around the world, with 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Wednesday, December 4th, 2019 Uncategorized Comments Off

$SGLB Releases Q3 Numbers, Remains at the Forefront of Next Industrial Revolution

December 4, 2019

  • Company reports increased revenue over last year’s Q3 numbers
  • Key operational highlights point to even stronger revenue growth moving into 2020
  • Sigma Labs’ pioneering software provides essential element to spur additive manufacturing into the next industrial revolution

Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D-printing industry, reported its financial and operational results for the third quarter ended Sept. 30, 2019 (http://nnw.fm/8dSvw). The company noted that recent progress with original equipment manufacturers (OEMs), end users and additive-manufacturing integrators positions SGLB for strong revenue growth in 2020.

“The third quarter of 2019 was highlighted by continued success in engaging both OEMs and end users as PrintRite3D(R) customers, driving continued industry awareness and developing promising commercial opportunities,” said Sigma Labs chairman and CEO John Rice. “Notably, we were recently selected by a major Japanese OEM machine-tool manufacturer entering the commercial, metal 3D-printing market, as well as an unnamed major international OEM machine manufacturer, to deploy PrintRite3D systems for their respective evaluation programs. We believe a partnership to integrate our technology at the OEM level for any major additive manufacturing machine OEM, such as those we are in evaluations with now, could drive notable license revenue growth in the short term and very significant pass-through revenue from the OEM’s customers in the mid and long term.”

He continued, “We are pleased and encouraged by the robust interest we continue to see from industry OEMs and look forward to providing our shareholders with an update as these evaluations progress over the next several months.” This increased interest from OEMs stands to translate into lucrative gains for SGLB. Market indications continue to trend upward, as the global additive manufacturing market is expected to exceed more than $6.50 billion by 2024 and will grow at a CAGR of more than 13% in the given forecast period (http://nnw.fm/EQQ3c).

In its Q3 2019 report, Sigma Labs pointed to several significant operational milestones, including:

  • Awarded two-machine contracts and selected for a Phase 2 test and evaluation program of PrintRite3D in-process, quality-assurance software by a leading global-energy technology company
  • Selected by major Japanese OEM machine-tool manufacturer for a test and evaluation program of PrintRite3D real-time melt pool analytics
  • Awarded RTE contract by VTT Technical Centre of Finland to install PrintRite3D at the VTT 3DMetalprint Centre for Additive Manufacturing
  • Selected by a major international OEM machine manufacturer to deploy two PrintRite3D quality-assurance software programs as part of an evaluation process for a broader rollout
  • Selected by Airbus to deploy the PrintRite3D version 5.0 software product into a fusion printer as part of a testing and evaluation program ahead of a larger potential commercial rollout throughout the Airbus organization.

In addition, this week SGLB’s chief technology officer Darren Beckett presented and demonstrated PrintRite3D at Formnext 2019, the leading global exhibition on additive manufacturing, held in Frankfurt, Germany.

“Additive manufacturing is, in our mind, undoubtedly the next industrial revolution,” said Rice. “And we are on the forefront of revolutionizing an essential element for its widely forecast leap to serial manufacturing. The flexibility inherent to additive manufacturing, combined with the increased quality and decreased risks, waste and costs accomplished with our PrintRite3D technology, create an unbeatable combination.”

Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D advanced manufacturing technologies. SGLB’s advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 4th, 2019 Uncategorized Comments Off

$OGI Announces Establishment of At-The-Market Equity Program

Organigram Holdings (NASDAQ: OGI) (TSX: OGI) today announced that it has established an at-the-market equity program (“ATM Program”) that allows the corporation, at its discretion, to issue up to C$55,000,000 (or its U.S. dollar equivalent) of common shares from treasury to the public from time to time. Any common shares sold in the ATM Program will be sold through the Toronto Stock Exchange, the NASDAQ Global Select Market or any other marketplace on which the common shares are listed, quoted or otherwise traded, at the prevailing market price at the time of sale. The corporation, at its sole discretion, will determine the volume and timing of distributions under the ATM Program, if any.

To view the full press release, visit http://cnw.fm/fk7Sd

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select Market and a Toronto Stock Exchange (“TSX”) listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the company is regulated by Health Canada under the Cannabis Act (Canada) and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.Organigram.ca.

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://cnw.fm/OGRMF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 4th, 2019 Uncategorized Comments Off

$YGYI Why Some People May Cough When They Vape CBD

December 4, 2019

Cannabidiol (CBD) has been having a ton of good press over the past few years. Extracted from legal industrial hemp, the compound is choke-full of potent medicinal properties, perfectly capable of kicking a variety of conditions to the curb. The long list of medical conditions CBD is effective against ranges from insomnia and anxiety to severe issues like chronic pain and pediatric epilepsy.

Aside from its medical benefits, cannabidiol can be used in diverse ways, ranging from tinctures, edibles, and topicals to vaping. Arguably, vaping is the fastest way to experience the effects of CBD since it doesn’t have to go through the digestive tract. It’s absorbed straight into the blood, and it acts on the endocannabinoid system (ECS) faster than it would have through any other means.

However, coughing is often associated with vaping, and it can make the entire process frustrating and unenjoyable. So, why do you think some people tend to cough when they vape? For starters, your lungs and the lining of your throat are extremely sensitive. And while you may think that CBD is the big bad that sends you into hacking coughs, that’s not the case. The chances of you descending into a coughing fit after vaping CBD isolate would be zero to none.

The real culprits are terpenes. These are aromatic organic hydrocarbons produced by the cannabis plant, just like cannabidiol. Terpenes are also medically beneficial, and when used in concert with CBD the combination is even more effective. This has been termed the entourage effect. However, they are very strong chemicals, and they can be quite acrid and irritating when heated. So a vape with a higher concentration of terpenes will be harsher on the throat.

The second culprit is the carrier liquids the CBD is dissolved into. While few people seem to have a reaction to MCT coconut oil, quite a number of people are somewhat allergic to vegetable glycerin (VG). Propylene Glycol (PG), on the other hand, packs quite a punch. Not to mention, the carrier liquids turn into hot, dry vapor when vaporized, and this will irritate the lungs and throat lining. Many users find it easier on their lungs when they set the vaporizer to a lower temperature.

At the end of the day, chances are you will put up with some sort of irritation when you vape CBD. Investing in vapes with milder carrier liquids, vaping at lower settings and keeping a glass of cold water close by will help. Ultimately, with more use, you will become accustomed to the harsh, hot air and will therefore cough less.

Experts believe that few CBD users have such helpful information, and this could explain why the more successful CBD companies like Youngevity International Inc. (NASDAQ: YGYI) and Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) invest a lot in consumer education.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Wednesday, December 4th, 2019 Uncategorized Comments Off

$SRAX Bolsters BIGtoken’s Entry into Market Research, Partners Exchange Platform: Cint

SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announced its partnership with Cint to leverage the BIGtoken platform to gather insights for brands. According to the update, Cint has the world’s largest online sample exchange, and its platform automates sample fieldwork and operations for insights companies to gather research data faster, more cost-effectively and at scale. “This partnership bolsters BIGtoken’s entry into the market research ecosystem,” Kristoffer Nelson, COO of SRAX and co-founder of BIGtoken, said in the news release. “Cint is one of the world’s largest solutions to help accelerate consumer insights for top brands including many of the Fortune 500. BIGtoken will leverage Cint’s technology, and we expect client relationships to build another recurring revenue stream beginning in the first quarter of 2020.”

To view the full press release, visit http://nnw.fm/9Us1F

About SRAX Inc.

SRAX (NASDAQ: SRAX) is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 4th, 2019 Uncategorized Comments Off

$POAI Platform Revolutionizing Cancer Treatment

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven, precision-medicine company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. An article discussing the company reads, “POAI’s platform, composed of over 150,000 patient tumors, harnesses the power of an individual patient’s tumor to help recommend the best treatment for that patient. This database, which houses evidence documenting actual drug responses of cancer patients’ individual tumors, uses artificial intelligence to create a valuable predictive tool for pharmaceutical companies and researchers. . . . Industry leaders believe that models utilizing patient-derived data powered by artificial intelligence will allow doctors to make more effective individualized treatment recommendations, changing the landscape of cancer treatment. The predictive models can be applied clinically for patients of today, and they can also be used in the development of new drugs by researchers to help cancer patients of tomorrow.”

To view the full article, visit http://nnw.fm/2sEFv

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through five segments (domestic, international, clinical, CRO and DCHIP), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical) and an AI-powered, proprietary bioinformatics platform (DCHIP) to provide tailored solutions to clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. POAI’s proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 4th, 2019 Uncategorized Comments Off

$GWPD Controlled Environment Micro-Farms as Partial Solution Amidst Recent E. Coli

GP Solutions (OTC: GWPD), the developer of modular automated micro-farms, may help in solving the E.coli crisis that is sickening dozens across America according to Business Management News. Per the article, dozens of people were infected across 19 states in the most recent E. coli outbreak stemming from lettuce harvested in California. Of those infected, their ages range from 3 to 89 years old, with 39 requiring hospitalization and six developing kidney failure. The article discusses forward-thinking companies that have developed new indoor farming methods, and references GWPD as it states, “One such company is GP Solutions. The company developed what they call a ‘GrowPod.’ Essentially, a food-grade shipping container, refurbished and outfitted with the latest technology to grow clean food in a controlled environment. Inside a GrowPod, the air and water are filtered, and since it is a sealed environment, there is little chance for contamination.”

To view the full press release, visit http://nnw.fm/GRx07

About GP Solutions, Inc.

GP Solutions, Inc. is the developer of highly innovative automated micro-farms trade named “GrowPods.” GrowPods are a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. Offering fully insulated, food-grade shipping container that has been specifically modified to provide the optimum controlled environment for growing a wide range of horticultural and agricultural products in all environments and climates. With the company’s combination of hydroponic and certified organic soil systems, clients can produce a significantly higher yield that grows faster, healthier and more consistent. For more information, visit the company’s website at www.GrowPodSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to GWPD are available in the company’s newsroom at http://nnw.fm/GWPD

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 4th, 2019 Uncategorized Comments Off

$YGYI 420 with CNW – DEA Puts Final Touches to 2020 Marijuana Cultivation Plans

December 3, 2019

The Drug Enforcement Administration’s (DEA) plans for authorizing the cultivation of 3.2 million grams of marijuana for research purposes in the 2020 planting season has been finalized. The 3.2 million grams is a 30% increase from 2019.

In September, the DEA published a notice in the Federal Register which proposed the 3.2 million grams production of weed. The final notice to be released includes the sentiments of the people collected during the public comment period, which were from the health care providers, the general public, and state and federal officials.

Most of the comments focused on the proposed reduction of opioid production by the DEA, citing that this could result in a shortage in the prescription, which could impact the patients negatively.

However, the DEA still decreased production quotas for certain opioids such as oxymorphone and oxycodone. The initial production of Oxycodone was 72, 593,983 grams, but the DEA reduced the final quota to 67,593,983 grams.

The marijuana production quota did not change at the end of the public comment timeline.

According to the DEA, the quota represents the estimated medical, scientific, study, and industrial needs of the U.S. for legal export requirements, and the establishment and preservation of reserve stock. The DEA further said that there has been an increase in demand for research-grade cannabis, and more states are legalizing marijuana for medical or adult-use purposes.

In the initial notice, compared to 2017, the number of agencies registered with the DEA to conduct marijuana research or on its derivatives, extracts, and THC has increased by 40% in 2019. In 2017, the number of registered agencies was 384, and by January 2019, the number had risen to 542.

Despite the increase in the marijuana production quota and the number of registered researchers, there is only one marijuana cultivation facility that is authorized by the federal government, the University of Mississippi farm. Three years have passed since the DEA said that it would approve additional manufacturers of research marijuana, but it is yet to take action.

This summer, scientists filed a lawsuit against the DEA, arguing that it is using delaying tactics and failing to fulfill its duties of approving more than 24 applications for federally approved marijuana growers.

In August, the DEA made an announcement saying that due to the overwhelming number of applications, the agency had developed alternative regulations for processing the applications. This resulted in the dismissal of the lawsuit before the federal court since the agency was taking the necessary measures to resolve the issue brought before court.

Researchers and legislators also said that the University of Mississippi farm does not have all the marijuana products being traded on the market. Some of the marijuana contains lower levels of THC and other cannabinoids, which undermines the quality of the studies.

According to one study, the chemical composition of marijuana from federal farms was closer to that of hemp than of other marijuana available on the market, and this made it more urgent to license additional producers for research-grade marijuana.

Industry watchers are certain that marijuana companies, such as Youngevity International Inc. (NASDAQ: YGYI) and Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), may have preferred that the federal agency announces additional producers so that the larger production quota can avail the quality of marijuana needed by researchers.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Tuesday, December 3rd, 2019 Uncategorized Comments Off

$SRAX Reports Significant Growth in User Base, Global Expansion in Q3

December 3, 2019

  • SRAX holds competitive advantage as big brands seek solutions that legacy partners cannot address
  • Thousands joining BIGtoken platform daily with minimal marketing
  • Four nonprofits, three CPG brands added to opt-in platform, increasing usage, reputation and reach

SRAX Inc. (NASDAQ: SRAX) sits at the epicenter of consumer privacy and data ownership. Leveraging its BIGtoken platform, the Company has made it possible for consumers to own their own data and get paid for the release of that data while also creating specific data sets around highly valuable verticals. On November 13, 2019, SRAX hosted a conference call for executives to share Q3 earnings and a forward look into Q4 with investors (http://nnw.fm/72m3W).

“Consumers are awakening to their online privacy and value exchange that exists for their personal information,” George Stella, SRAX’s vice president for brands and shopper marketing, stated in a news release. “Privacy regulations are happening fast now with California or CCPA and other states taking hold, and these conditions are creating a competitive advantage for us because big brands are moving to find solutions that their legacy partners can no longer address.”

These changes, both in the United States and globally, along with the ability to provide brands with a complete view of a consumer’s journey, have given SRAX a distinct competitive advantage. The BIGtoken platform is the means by which consumers are enabled to own their own data. As of the call, subscriber base has grown to 16.3 million users with minimal marketing spending, positioning the Company as a leader in this space. The platform continues to see anywhere from 3,000 to 10,000 people join a day.

The platform has expanded globally and is listed in the top 100 applications in the App Store and Google Play. The opt-in, user-controlled data set has proven to be the perfect remedy to GDPR’s impact. In addition to the acceptance it has seen in the 28 member countries of the European Union, the platform has also seen significant growth in Brazil, Indonesia, Italy and the Philippines. SRAX is strongly positioned to conduct research worldwide for big brand global organizations.

During Q3, BIGtoken added the ability for consumers to donate their earnings to the American Heart Association, HealthCorps, The ALS Association and Keep a Child Alive. Users from more than 20 countries have already donated to these nonprofits. During this same time, the Company’s BIG Rewards program, an exclusive offer for consumers to redeem earnings at specific retailers, added Procter & Gamble, Kraft and Sun-Maid. These three major CPG brands evaluated the platform and saw it as an innovative way to gain quality data.

The BIG Rewards program creates additional revenue for the organization while also bringing new users to the BIGtoken platform. The program allows companies access to a user base that has high privacy settings on social media, a consumer group that brands might typically have a hard time reaching.

A second platform, SRAX IR, is focused on helping CEOs and CFOs identify, manage and communicate with their investor base in groundbreaking ways. A few of the platform’s features include the ability to track shareholders’ behaviors and trends over time, get real-time market data including your company’s level two data, and engage shareholders across marketing channels including social media, email, and programmatic. Subscribing companies can utilize SRAX to turn their shareholder base into a revenue stream.

Additional verticals allow SRAX to sell access to specific data sets to an increasing number of brands. The two platforms are being leveraged to build crossover into the verticals. “We spent the past few quarters integrating our platforms and realigning the sales process and are now well positioned for growth,” added SRAX CEO Christopher Miglino. “Looking ahead, we expect to accelerate revenue by engaging with big brands across all three of our platforms.”

As the demand for data insights increase, SRAX is confident in growth prospects across its verticals. During Q3, the Company raised $5.5 million through a registered direct offering. As of September 30, 2019, SRAX reported being debt free, having cash and cash equivalents on hand of $2.8 million, and having approximately 13.9 million shares outstanding compared to 9.9 million in September 2018.

The best way to understand the BIGtoken platform is to join and discover how surveys are conducted and consumers are given control over personal data.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Tuesday, December 3rd, 2019 Uncategorized Comments Off

$SGLB Awarded Phase 2 RTE Contract, Gaining Traction in Additive Manufacturing Industry

December 3, 2019

  • SGLB awarded final phase of RTE contract with leading global energy technology company
  • Successful completion of Phase 2 contract could result in material commercial order from global client
  • Sigma Labs establishing enviable position in 3D printing industry with breakthrough PrintRite3D software

Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D-printing industry, announced that it has been awarded a Phase 2 rapid test and evaluation (RTE) contract by a leading global energy technology company. This final phase of an RTE contract is required to enable end-users to make a purchase decision on deploying Sigma’s technology in serial production (http://nnw.fm/ft3Bm).

The two-machine contract for the deployment of Sigma Lab’s PrintRite3D(R) in-process quality assurance software comes after the successful Phase 1 completion of the rapid test and evaluation (RTE) program. Sigma Labs anticipates that a successful Phase 2 RTE outcome could result in a material commercial order from the customer that would integrate PrintRite3D into existing dedicated commercial production machines. This contract has significant implications for Sigma as it continues to penetrate the global energy service sector (http://nnw.fm/qhG10), which has been “projected to reach USD 86.9 billion by 2024 from an estimated USD 52 billion in 2019.”

“The conversion from our initial test and evaluation program to the Phase 2 pilot rollout is a testament to the traction our enabling technology is garnering in the additive manufacturing industry,” said Sigma Labs chairman and CEO John Rice. “We look forward to working with this well-respected industry leader known for their innovative technology and superior service to drive improved and serial printing quality on their production lines.”

It wasn’t revealed until the Q3 earnings call that the RTE customer is Baker Hughes. Baker Hughes provides technology and services that enable oil and gas companies in more than 120 countries to deliver safe, affordable energy to the world. Baker Hughes’ vast technological prowess creates value by developing new ways to improve well construction efficiency, integrates technology and services to develop new solutions that accelerate and optimize hydrocarbon production, and researches new ways to increase ultimate recovery.

The announcement of the Phase 2 contract was followed with other impressive news from Sigma as it continues to gain traction and recognition in the industry. The company was also selected by a major Japanese OEM machine tool manufacturer for a test and evaluation program of PrintRite3D’s real-time, melt-pool analytics (http://nnw.fm/1mE9C). SGLB was also awarded a contract by VTT Technical Centre of Finland to install PrintRite3D at the VTT 3DMetalprint Centre for Additive Manufacturing, enabling VTT to best support its customers’ development activities.

Sigma Labs is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection solutions for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, thereby allowing errors to be corrected in real time.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Tuesday, December 3rd, 2019 Uncategorized Comments Off

$GGBXF CBD Companies Say Lack of FDA Rules is Hurting Their Businesses

December 3, 2019

The cannabidiol (CBD) industry has seen massive growth in the past few years. Valued at $1.8 billion in 2018, the US CBD market is expected to hit $16.32 billion by 2026, a compound annual growth rate of 27.7%. The genesis can be traced back to the 2018 Hemp Farming Act, legislation that legalized the cultivation of industrial hemp, the plant from which cannabidiol, touted as a miracle drug, is extracted.

Bolstered by this regulation, tons of sellers streamed into the industry, some dealing in hemp farming and others dealing with the CBD end. However, despite the fact that there is obviously an immense market, companies that specialize in CBD-infused products have been having a hard time keeping their profits up. CV Sciences and Charlotte’s Web are among the cannabis companies going through this, and according to them, delayed federal CBD regulations are to blame.

“The absence of an interim or final regulatory framework from the FDA has led to a very low barrier of entry for new companies entering the CBD category, which has led to increased competition especially in the natural product retail channel,” says CV Sciences CEO Joseph Dowling. The company reported a revenue of $12.6 million from the third quarter that ended on September 30, a decrease of more than 7% from the same period last year. He adds that the delay has also made national retailers slow to embrace CBD.

Charlotte’s Web, on the other hand, reported revenue of $25.1 million, a 42% increase from the $17.7 million reported in the same period in 2018. However, analysts had put 2019’s reported revenue at $31 million after the company crossed 9,000 retail outlets. According to Charlotte’s Web’s executives, a lack of regulatory direction from the FDA is slowing down growth in food, drug, and mass sales channels. CEO Deanie Elsner adds that “Full revenue growth potential remains dampened due to a lack of regulatory clarity for ingestible CBD products.”

What’s ironic is that while the USDA has taken steps to further regulate hemp with the issuing of the interim final rule on hemp, it has mostly ignored CBD. As Denver cannabis attorney Frank Robinson poses, one end of the supply chain is experiencing strict rules while the other end remains uncertain. “It’s befuddling to me that we’re keying these THC tests off the flower, but nevertheless all of the products that are made from the flower downstream aren’t being directly and actively regulated by the appropriate federal agency,” he adds.

The FDA has made it public that it will not bow to political pressure to hastily regulate CBD products, saying that more research on the effectiveness and side effects of CBD has to be done before it can move forward with regulation.

Analysts believe that that frustrations expressed by Charlotte’s Web and CV Sciences in the discussion above possibly reflect the think of all industry players, such as Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and No Borders Inc. (OTC: NBDR), since they are all affected by the circumstances enumerated by the firms highlighted.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Tuesday, December 3rd, 2019 Uncategorized Comments Off

$RIV.V $CNPOF Wisconsin Governor Signs Hemp Production Bill

December 3, 2019

On Tuesday, Wisconsin Governor Tony Evers signed a hemp production legislation that amends laws governing industrial hemp cultivation. He also signed a bill legalizing temporary lemonade stands for children under the age of 18.

The bill, which was approved by both the Democrats and Republicans, re-authorizes the growth of hemp and makes several changes to the Wisconsin hemp regulations. Supporters of the bill said that Wisconsin law needed to be updated after Congress legalized hemp production under the 2018 Farm Bill. The 2018 Farm Bill urged states interested in the cultivation of hemp to enact new state regulations in line with the rules passed by the USDA.

Sen. Patrick Testin applauded the governor Evers for approving the bill affirming that it is a step in the right direction as hemp becomes re-introduced in the state.

In a statement, Testin said that the signing of the bill marked the beginning of a new era for the farmers, processors, retailers, and consumers from the state of Wisconsin.

The production of industrial hemp was legalized in Wisconsin in 2017. The plant is used in making products such as fabrics, lotions, ropes, and granola bars.

Hemp was not legal in the state of Wisconsin for several decades as it was outlawed for containing small amounts of THC, which is the compound of marijuana that gets you high.

According to the DATCP (Department of Agriculture, Trade and Consumer Protection), the state of Wisconsin awarded 1,247 farmers with cultivation licenses, and 556 hemp processing permits in 2019.

Wisconsin regulations stipulate that growers and processors must pass a background check, and those who have past drug convictions are not permitted to grow or process the crop. The plants must undergo THC testing and those containing more than 0.3% THC must be destroyed.

Some farmers raised concerns and said that delays in testing the crop by the state could lead to increased THC concentration, which would lead to the eradication of their plants.

Sponsors said that the new regulation would give the state’s Department of Agriculture the chance to hire third-party labs to help in testing the crops.

Governor Evers said that the crop provides the people of Wisconsin looking to venture into new markets with a sea of opportunities.

Last week, the governor also approved several bills into law, which would ensure that:

  • People who are 18 years and below are allowed to own and operate a lemonade stand without a permit. The proposal also barred the passing of ordinances banning the temporary stands by the local government.
  • The conditions for awarding educational loan assistance were expanded to health care providers such as doctors, nurses, and dentists providing services in free marijuana clinics.
  • Non-profit organizations and employees providing care to homeless people to be covered by the state’s liability insurance.
  • Require wetland mitigation near a construction site, a move that would protect the city against flooding, protect groundwater from pollution, and preserve the environment.
  • Allow gas pumps to dispense fuel containing less than 10% or 15% ethanol, and gasoline which is not infused with ethanol through the fueling nozzle and hose.

The enactment of the hemp law in Wisconsin is likely to be a piece of good news to the entire industry, including players like Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) and Dama Financial, which have always wanted to see hemp programs implemented across the nation.

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

HempWireNews is part of the InvestorBrandNetwork.

Tuesday, December 3rd, 2019 Uncategorized Comments Off

$YGYI Khrysos Industries Brings Triple Distillation System On Line in Florida Facility

Youngevity International (NASDAQ: YGYI), a leading omni-direct lifestyle company, together with its wholly-owned subsidiary, Khrysos Industries, Inc., today announced that Khrysos has brought a new triple distillation system online at its recently leased 82,000 square foot post processing and finished goods production facility in Orlando, Florida. According to the update, the new system is planned to be used exclusively for hemp oil remediation on a toll processing basis. In addition, Khrysos Industries announced that the company has increased capabilities in Isolate production by bringing online two 150 Isolate Reactors, expected to increase its ability to produce Isolate by 6-fold. “We are seeing a high demand for hemp oil remediation and tolling capabilities in our industry.  We believe expanding our tolling capacity places our company in a unique position to generate revenue in multiple segments of the market,” YGYI President and CFO Dave Briskie said in the news release.  “Being able to provide turn-key solutions in a triple distillation facility should provide unique competitive advantages that we anticipate will expand our customer base and drive revenue while improving our opportunity to drive our bottom-line profits.”

To view the full press release, visit http://cnw.fm/kG7P1

About Youngevity International

YGYI, Inc. (NASDAQ: YGYI), is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, YGYI offers products from the eight top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, fashion, essential oils, photo, as well as innovative services. The Company was formed in the course of the summer 2011 merger of Youngevity Essential Life Sciences with Javalution(R) Coffee Company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For investor information, please visit www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://cnw.fm/YGYI

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

HempWireNews is part of the InvestorBrandNetwork.

Monday, December 2nd, 2019 Uncategorized Comments Off

$RIV.V $CNPOF Marijuana Companies Look to Europe for Greener Pastures

December 2, 2019

Marijuana companies in North America are experiencing lots of trouble, and companies that are looking to reap profits from cannabis are suffering from significant losses. In the meantime, European companies such as World High Life PLC are basking in the new opportunities brought by the emerging marijuana industry.

The marijuana sector needs a fresh look because its markets remain unattractive despite the changes in equity valuation and investor attitudes.

Canopy Growth holds the blue-chip marijuana market leader position. Before Constellation Brands Inc. acquired its first stake in 2017, Canopy Growth had already secured a significant amount of funds.  A few days before marijuana was legalized in Canada; Canopy Growth shares increased by $55.45 (C$73.75). However, the stock price has dropped by 73% since then, and within the past six months, the company recorded the highest losses ever.

Canopy Growth shares were valued at $18 billion (C$24 billion) by the stock market at the end of April 2019. At the moment, the value at the stock market has dropped to less than $5.2 billion (C$7billion). Compared to the first quarter, the company’s sales were down 15% in the second quarter.

Apart from Canopy, other companies suffering from the downturn in marijuana market are Aphria Inc. whose shares have fallen 59% since April, and Aurora Cannabis Inc. whose shares have fallen 76% since the end of the first quarter of 2019. In the marijuana sector, companies are struggling with declining liquid assets, expensive operations, and shareholder attenuation.

On Tuesday, some pot stocks recorded a rise. Companies like the Horizons Marijuana Life Sciences (ETF), which holds dozens of marijuana stocks recorded a 4.9% increase in stock trading. This suggests that investors are beginning to see the opportunities in marijuana stocks. Canopy stock also recorded a rise of $1.53, which is equivalent to 8.2%.

The marijuana market in North America is struggling with a fall in stock prices and surplus marijuana; however, the investors are investing more and more in the European emerging marijuana industry since they do not want to miss out on the new opportunity.

In a few years, the new frontier market in Europe may become the most significant market around the globe. It is estimated that by 2029, the medical marijuana market in Europe and the UK will be worth approximately $64.2 billion (£58 billion).

One of the companies that have taken full advantage of the emerging cannabis market in the UK is the World High Life PLC. The company plans to become a world leader in the global medical cannabis market as the industry evolves in the UK and Europe.

World High Life PLC finds and purchases marijuana companies in the UK and different European countries, thus creating a portfolio of companies with the capability of being top players in the marijuana industry. Investors are aware that buying a single stock in WHL gives you access to all the shares in the company.

The new frontier market gives investors and organizations a new chance to invest in the marijuana industry since they did not initially invest when marijuana was first legalized in Canada.

Experts think it may not be long before we witness an influx of companies like No Borders Inc. (OTC: NBDR) and Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) into the European market as a way of getting a piece of the offshore marijuana pie.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Monday, December 2nd, 2019 Uncategorized Comments Off

$OGI New York to Drop Charges in Mistaken Hemp Case

December 2, 2019

A New York man charged with felony marijuana trafficking charges can finally heave a sigh of relief after Brooklyn prosecutors said they would drop his charges. Ronen Levy was receiving a shipment of hemp from Fox Holler Farms in New Haven, Vermont, in place of his brother John Dee, when he was arrested by the New York City Police.

Believing it to be marijuana, the police confiscated 106 pounds of organic hemp, even posing for pictures with what they thought to be a major haul of illicit cannabis. Dee, who runs Green Angel, a business in Brooklyn that makes cannabidiol (CBD) products, says that the police need to be better educated about hemp. “There’s a lot of regulations out there, and I think law enforcement has to actually learn these regulations and has to learn the law so other people don’t have to go through what we went through.”

Granted, marijuana and hemp look quite similar, and although there are minor physical differences, the legality depends on THC (delta-9 tetrahydrocannabinol) levels. THC is the compound responsible for the psychoactive high cannabis is famous for.  Dee had made sure to include documents verifying that the hemp contained 0.06% THC and that he had hemp verified by the Williston police before sending it over by FedEx.

This is line with the 2018 Hemp Farming Act that classified cannabis with less than 0.3% THC as legal industrial hemp and gave farmers in all 50 states leeway to grow the crop under state programs.

Dee says that his brother, who isn’t involved with the cannabis industry and was just receiving the shipment on his behalf, has been traumatized by the incident. Oren Yaniv, a spokesman for the Brooklyn District Attorney’s Office says the charges haven’t been dismissed yet, but they will. “The prosecutor said on the last court date that we plan to dismiss them and just have to take a few steps prior to that.”

The hemp farmer wonders whether he will be able to get his shipment back from police possession. It is worth $17,500, but once processed, he expects the value to increase to about $50,000. “I’m praying because it’s my life savings.”

The whole incident hasn’t done wonders for his Brooklyn business either. He says that Green Angel has struggled to stay afloat amid all the publicity surrounding his brother’s arrest and subsequent charges. Afraid of getting any negative shine on them, suppliers have cut him off, he says, adding that customers are now afraid to buy products from his shop. “It’s crippled my business.”

Such unfortunate incidents may be what experts regard as the motivation for hemp industry players like Hemptown USA and Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) to call on all law enforcement agencies to avoid being overzealous when presented with documents indicating that a product is hemp and yet they suspect it to be marijuana.

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

HempWireNews is part of the InvestorBrandNetwork.

Monday, December 2nd, 2019 Uncategorized Comments Off